| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9328364 | Gynecologic Oncology | 2005 | 8 Pages |
Abstract
Ã
6 given daily continuously is well tolerated at all dose levels, without any dose-limiting toxicity. Based on the preliminary activity of Ã
6, a phase II trial is underway in ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Anna Berkenblit, Ursula A. Matulonis, Joan F. Kroener, Bruce J. Dezube, Gil N. Lam, Luceli C. Cuasay, Nils Brünner, Terence R. Jones, Michael H. Silverman, Michael A. Gold,